<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Basic fibroblast growth factor (bFGF) is a <z:chebi fb="1" ids="15841">polypeptide</z:chebi> with potent survival-promoting and protective effects on brain cells </plain></SENT>
<SENT sid="1" pm="."><plain>In previous studies, we showed that intravenous administration of bFGF reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume in models of focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in rats, mice, and cats </plain></SENT>
<SENT sid="2" pm="."><plain>In these previous studies, <z:mpath ids='MPATH_124'>infarct</z:mpath> volume was measured within 1-7days of the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The current study was undertaken to determine whether the reduction in <z:mpath ids='MPATH_124'>infarct</z:mpath> volume by bFGF was persistent beyond the first week after <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Mature male Sprague-Dawley rats received an intravenous infusion of bFGF (50 microg/kg per h) or vehicle during 0.5-3.5h after permanent proximal middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>We found a 27% reduction in <z:mpath ids='MPATH_124'>infarct</z:mpath> volume in bFGF- compared to vehicle-treated animals at three months after infarction (P&lt;0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>The data show that intravenous bFGF treatment produces a persistent reduction in <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, at least up to three months following focal <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>